Searching for therapies inhibiting only IGF-1R kinase activity may appear to invalidate the IGF-1R as a target for cancer therapy, while many potential drugs that modify alternative downstream effects, the “biasing agonists”, are not considered. The gene discussed is IGF1R; the disease is cancer.